Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

KETOROLAC TROMETHAMINE

Form:

8 of 8 products shown

3 general benefit · 5 not a benefit

Other products in the same Health Canada class (M01AB, S01BC) — coverage varies; not interchangeable

  • Diclofenac (Voltaren): general benefit, Not a benefit
  • Diclofenac + misoprostol (Arthrotec 50): general benefit
  • Indomethacin (Indocid): general benefit, Not a benefit
  • Sulindac (Clinoril): general benefit, Not a benefit
  • Bromfenac (Prolensa): not a benefit
  • Diclofenac (Voltaren Rapide): not a benefit

17 more in the class list below

Acuvail · DIN 02369362 · 0.45% w/v · Oph Sol-0.4mL vial (Preservative-Free)

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Acuvail · DIN 02369362 Manufacturer: AbbVie Corporation; listing date 2013-04-30 Health Canada: Marketed since 2024-06-04 · brand ACUVAIL · ATC S01BC05 KETOROLAC · form Solution · route Ophthalmic · ingredients KETOROLAC TROMETHAMINE 0.45 %/W/V · company Abbvie corporation · schedule Prescription
Check this DIN again · Health Canada product record

Acuvail: Formulary list price $0.2593/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2593 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85428 · Verify on the e-Formulary ↗ (DIN 02369362)

Source record
DIN 02369362: Acuvail Raw flags: sec3=Y Item: 520800046; group id 597; item number 1557; lccId None; manufacturer id ABV Source form: Oph Sol-0.4mL Vial Pk (Preservative-Free); strength: 0.45% w/v Recorded listing: General benefit Source prices (unrounded): $0.2593; ministry $0.2593 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02369362 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85428
Shortage status: resolved shortage (ended 2021-12-31); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02369362
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Acular · DIN 01968300 · 0.5% · Oph Sol

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Acular · DIN 01968300 Manufacturer: Allergan Inc.; listing date 1996-10-01 Health Canada: Marketed since 2023-10-05 · brand ACULAR · ATC S01BC05 KETOROLAC · form Solution · route Ophthalmic · ingredients KETOROLAC TROMETHAMINE 0.5 %/W/V · company Abbvie corporation · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $2.8997 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13121 · Verify on the e-Formulary ↗ (DIN 01968300)

Source record
DIN 01968300: Acular Raw flags: sec3=Y Item: 520800030; group id 597; item number 1556; lccId None; manufacturer id ALL Source form: Oph Sol; strength: 0.5% Recorded listing: General benefit Source prices (unrounded): $3.6780; ministry $2.8997 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01968300 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13121
Interchangeable products
Ketorolac · DIN 02245821 · $2.8997
Shortage status: resolved shortage (ended 2026-07-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01968300
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Ketorolac · DIN 02245821 · 0.5% · Oph Sol

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Ketorolac · DIN 02245821 Manufacturer: A A Pharma Inc.; listing date 2004-07-20 Health Canada: Marketed since 2014-08-19 · brand KETOROLAC · ATC S01BC05 KETOROLAC · form Solution · route Ophthalmic · ingredients KETOROLAC TROMETHAMINE 0.5 % · company Aa pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Ketorolac: Formulary list price $2.8997/unit (unit not stated in source; not the patient's cost)

Ministry pays: $2.8997 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69937 · Verify on the e-Formulary ↗ (DIN 02245821)

Source record
DIN 02245821: Ketorolac Raw flags: sec3=Y Item: 520800030; group id 597; item number 1556; lccId None; manufacturer id AAP Source form: Oph Sol; strength: 0.5% Recorded listing: General benefit Source prices (unrounded): $2.8997; ministry $2.8997 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02245821 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69937
Interchangeable products
Acular · DIN 01968300 · $2.8997
Shortage status: active shortage (reported 2025-10-07, estimated to end 2026-11-06, last updated 2026-06-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02245821
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Ketorolac · DIN 02229080 · 10mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Ketorolac · DIN 02229080 Manufacturer: Apotex Inc.; listing date 2008-10-01 Health Canada: Marketed since 2017-12-11 · brand APO-KETOROLAC · ATC M01AB15 KETOROLAC · form Tablet · route Oral · ingredients KETOROLAC TROMETHAMINE 10 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43510 · Verify on the e-Formulary ↗ (DIN 02229080)

Source record
DIN 02229080: Apo-Ketorolac Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 280804105; group id 385; item number 0923; lccId None; manufacturer id APX Source form: Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.6028; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02229080 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43510 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
Jamp Ketorolac · DIN 02510855 · not recorded Mar-Ketorolac · DIN 02465124 · not recorded Mint-Ketorolac · DIN 02461455 · not recorded Toradol · DIN 02162660 · not recorded
Shortage status: resolved shortage (ended 2025-03-20); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02229080
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Ketorolac · DIN 02510855 · 10mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Jamp Ketorolac · DIN 02510855 Manufacturer: Jamp Pharma Corporation; listing date 2021-04-30 Health Canada: Marketed since 2023-04-18 · brand JAMP KETOROLAC · ATC M01AB15 KETOROLAC · form Tablet · route Oral · ingredients KETOROLAC TROMETHAMINE 10 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100012 · Verify on the e-Formulary ↗ (DIN 02510855)

Source record
DIN 02510855: Jamp Ketorolac Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 280804105; group id 385; item number 0923; lccId None; manufacturer id JPC Source form: Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.6028; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02510855 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100012 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
Apo-Ketorolac · DIN 02229080 · not recorded Mar-Ketorolac · DIN 02465124 · not recorded Mint-Ketorolac · DIN 02461455 · not recorded Toradol · DIN 02162660 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02510855
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mar-Ketorolac · DIN 02465124 · 10mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Mar-Ketorolac · DIN 02465124 Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2017-08-30 Health Canada: Marketed since 2017-08-16 · brand MAR-KETOROLAC · ATC M01AB15 KETOROLAC · form Tablet · route Oral · ingredients KETOROLAC TROMETHAMINE 10 MG · company Marcan pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95332 · Verify on the e-Formulary ↗ (DIN 02465124)

Source record
DIN 02465124: Mar-Ketorolac Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 280804105; group id 385; item number 0923; lccId None; manufacturer id MAR Source form: Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.6028; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02465124 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95332 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
Apo-Ketorolac · DIN 02229080 · not recorded Jamp Ketorolac · DIN 02510855 · not recorded Mint-Ketorolac · DIN 02461455 · not recorded Toradol · DIN 02162660 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02465124
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mint-Ketorolac · DIN 02461455 · 10mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Mint-Ketorolac · DIN 02461455 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2019-11-29 Health Canada: Marketed since 2019-06-28 · brand MINT-KETOROLAC · ATC M01AB15 KETOROLAC · form Tablet · route Oral · ingredients KETOROLAC TROMETHAMINE 10 MG · company Mint pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94908 · Verify on the e-Formulary ↗ (DIN 02461455)

Source record
DIN 02461455: Mint-Ketorolac Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 280804105; group id 385; item number 0923; lccId None; manufacturer id MIN Source form: Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.6028; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02461455 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94908 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
Apo-Ketorolac · DIN 02229080 · not recorded Jamp Ketorolac · DIN 02510855 · not recorded Mar-Ketorolac · DIN 02465124 · not recorded Toradol · DIN 02162660 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02461455
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Toradol · DIN 02162660 · 10mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Toradol · DIN 02162660 Manufacturer: A A Pharma Inc.; listing date 2008-10-01 Health Canada: Marketed since 2018-07-30 · brand TORADOL · ATC M01AB15 KETOROLAC · form Tablet · route Oral · ingredients KETOROLAC TROMETHAMINE 10 MG · company Aa pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Toradol: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19348 · Verify on the e-Formulary ↗ (DIN 02162660)

Source record
DIN 02162660: Toradol Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 280804105; group id 385; item number 0923; lccId None; manufacturer id AAP Source form: Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02162660 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19348 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
Apo-Ketorolac · DIN 02229080 · not recorded Jamp Ketorolac · DIN 02510855 · not recorded Mar-Ketorolac · DIN 02465124 · not recorded Mint-Ketorolac · DIN 02461455 · not recorded
Shortage status: resolved shortage (ended 2018-07-30); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02162660
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary classes and how they are covered

Other drugs in the same formulary class (28:08:04 Nonsteroidal Anti-Inflammatory Agents) and how they are covered

Matched class: 28:08:04 Nonsteroidal Anti-Inflammatory Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: DICLOFENAC SODIUM & MISOPROSTOL Some products covered without a code (check the product listing): DICLOFENAC SODIUM, FLURBIPROFEN, IBUPROFEN, INDOMETHACIN, KETOPROFEN, MEFENAMIC ACID, MELOXICAM, NAPROXEN, PIROXICAM, SULINDAC, TIAPROFENIC ACID 28:08:04 Nonsteroidal Anti-Inflammatory Agents

DICLOFENAC SODIUM

· 19 products · Listed, not a benefit (3), General benefit (11), Off-Formulary Interchangeable, not an ODB benefit (5) · strengths: 25mg, 50mg, 75mg, 100mg, 1.5% W/W · Ent Tab, LA Tab, Sup, Top Sol

DICLOFENAC SODIUM & MISOPROSTOL

· 6 products · General benefit · strengths: 50mg & 200mcg, 75mg & 200mcg · Tab

INDOMETHACIN

· 10 products · Listed, not a benefit (4), General benefit (6) · strengths: 25mg, 50mg, 100mg · Cap, Sup

SULINDAC

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 150mg, 200mg · Tab

DICLOFENAC POTASSIUM

· 4 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 50mg · Tab

FLURBIPROFEN

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 50mg, 100mg · Tab

IBUPROFEN

· 11 products · Listed, not a benefit (3), General benefit (8) · strengths: 200mg, 300mg, 400mg, 600mg · Tab

KETOPROFEN

· 9 products · General benefit (4), Listed, not a benefit (5) · strengths: 50mg, 100mg, 200mg · Cap, Ent Tab, LA Tab

MEFENAMIC ACID

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 250mg · Cap

MELOXICAM

· 14 products · Listed, not a benefit (2), General benefit (12) · strengths: 7.5mg, 15mg · Tab

NAPROXEN

· 21 products · Off-Formulary Interchangeable, not an ODB benefit (9), General benefit (8), Listed, not a benefit (4) · strengths: 250mg, 375mg, 500mg, 25mg/mL, 125mg · Ent Tab, O/L, Tab

PIROXICAM

· 6 products · Listed, not a benefit (2), General benefit (4) · strengths: 10mg, 20mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:08:04 and 6 more
Full class listing Related classes: 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:04 Antidepressants, 28:16:08 Tranquilizers, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists

Other drugs in the same formulary class (52:08 Anti-Inflammatory Agents) and how they are covered

Matched class: 52:08 Anti-Inflammatory Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: DEXAMETHASONE, FLUMETHASONE PIVALATE & IODOCHLORHYDROXYQUIN, FLUOROMETHOLONE, FLUOROMETHOLONE ACETATE, LODOXAMIDE TROMETHAMINE Some products covered without a code (check the product listing): BECLOMETHASONE DIPROPIONATE, BUDESONIDE, PREDNISOLONE ACETATE 52:08 Anti-Inflammatory Agents

BROMFENAC

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 0.07% w/v · Oph Sol (With Preservative)

DEXAMETHASONE

· 2 products · General benefit · strengths: 0.1% · Oph Oint-3.5g Pk, Oph Susp

FLUOROMETHOLONE

· 1 products · General benefit · strengths: 0.1% · Oph Susp

FLUOROMETHOLONE ACETATE

· 1 products · General benefit · strengths: 0.1% · Oph Susp

PREDNISOLONE ACETATE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 1% · Oph Susp

BECLOMETHASONE DIPROPIONATE

· 3 products · General benefit (2), Listed, not a benefit (1) · strengths: 50mcg · Nas-Sp-200 Dose Pk

BUDESONIDE

· 3 products · General benefit (2), Listed, not a benefit (1) · strengths: 64mcg/Metered Dose, 100mcg/Metered Dose · Nas Sp-120 Dose Pk, Nas Sp-165 Dose Pk

FLUMETHASONE PIVALATE & IODOCHLORHYDROXYQUIN

· 1 products · General benefit · strengths: 0.02% & 1% · Ot Sol

LODOXAMIDE TROMETHAMINE

· 1 products · General benefit · strengths: 0.1% · Oph Sol

AZELASTINE HCL & FLUTICASONE PROPIONATE

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 137mcg/Actuation&50mcg/Actuation · Nas-Sp-120 Dose Pk

FLUTICASONE PROPIONATE

· 4 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 50mcg/Actuation · Nas Sp-120 Dose Pk

MOMETASONE FUROATE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 50mcg/Dose · Nas Sp-140 Dose Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 52:08 and 2 more
Full class listing Related classes: 52:04 Anti-Infectives, 52:16 Local Anesthetics, 52:20 Miotics, 52:24 Mydriatics, 52:32 Vasoconstrictors, 52:36 Other Eye, Ear, Nose and Throat Agents Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS ACULAR® (ketorolac tromethamine ophthalmic solution 0.5% w/v) is indicated for:  the prophylaxis and the relief of postoperative ocular inflammation in patients undergoing cataract extraction with or without implantation of an intraocular lens. ACULAR LS® (ketorolac tromethamine ophthalmic solution 0.4% w/v) is indicated for:  the reduction of ocular pain and ocular symptoms of foreign body sensation, burning/stinging, tearing, and photophobia following refractive surgery. 1.1 Pediatrics Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics (> 65 years of age): No overall differences in safety or effectiveness have been observed between elderly and younger patients. https://pdf.hres.ca/dpd_pm/00068137.PDF PM date: FEB 12, 1992 Source product: ACULAR; DIN 01968300; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Ketorolac · DIN 02245821 Shortage status: active shortage (reported 2025-10-07, estimated to end 2026-11-06, last updated 2026-06-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02245821

Check this DIN again

Other review policies

For Apo-Ketorolac, Jamp Ketorolac, Mar-Ketorolac, Mint-Ketorolac, Toradol: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026